Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Receivables (2020 - 2025)

Agilon Health (AGL) has disclosed Receivables for 6 consecutive years, with $673.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 33.75% year-over-year to $673.8 million, compared with a TTM value of $673.8 million through Dec 2025, down 33.75%, and an annual FY2025 reading of $673.8 million, down 33.75% over the prior year.
  • Receivables was $673.8 million for Q4 2025 at Agilon Health, down from $947.2 million in the prior quarter.
  • Across five years, Receivables topped out at $1.6 billion in Q1 2024 and bottomed at $288.8 million in Q1 2021.
  • Average Receivables over 5 years is $880.3 million, with a median of $947.1 million recorded in 2023.
  • The sharpest move saw Receivables surged 133.21% in 2023, then crashed 33.75% in 2025.
  • Year by year, Receivables stood at $293.9 million in 2021, then surged by 69.87% to $499.3 million in 2022, then skyrocketed by 89.69% to $947.1 million in 2023, then grew by 7.39% to $1.0 billion in 2024, then plummeted by 33.75% to $673.8 million in 2025.
  • Business Quant data shows Receivables for AGL at $673.8 million in Q4 2025, $947.2 million in Q3 2025, and $1.0 billion in Q2 2025.